Studies of cardiotonic agents. 8. Synthesis and biological activities of optically active 6-(4-(benzylamino)-7-quinazolinyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone (KF15232)

Journal of Medicinal Chemistry

Volumn 39, Issue 1, 1996, Pages 297-303

  Nomoto, Yuji ^a   Takai, Haruki ^a   Okno, Tetsuji ^a   Nagashima, Ken ^a   Yao, Kozo ^a   Yamada, Koji ^a   Kubo, Kazuhiro ^a   Ichimura, Michio ^a   Mihara, Akira ^a   Kase, Hiroshi ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 BENZYLAMINO 7 QUINAZOLINYL) 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; 6 [4 (BENZYLAMINO) 7 QUINAZOLINYL) 4,5 DIHYDRO 5 METHYL 3(2H) PYRIDAZINONE; CALCIUM; CARDIOTONIC AGENT; CYCLIC AMP; CYCLIC GMP; MILRINONE; PHOSPHODIESTERASE; PYRIDAZINONE DERIVATIVE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATTLE; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTEREOISOMER; DOG; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; GUINEA PIG; HEART; HEART LEFT VENTRICLE PRESSURE; INOTROPISM; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; VASODILATATION;

ANIMALS; AORTA; CALCIUM; CARDIOTONIC AGENTS; CATTLE; DOGS; GUINEA PIGS; HEART FAILURE, CONGESTIVE; MALE; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; MYOCARDIAL CONTRACTION; NUCLEOTIDES, CYCLIC; PHOSPHODIESTERASE INHIBITORS; QUINAZOLINES; STEREOISOMERISM; TRIFLUOPERAZINE; VASODILATOR AGENTS; VENTRICULAR PRESSURE;

EID: 0030022892     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950197j     Document Type: Article

References (26)

1. Taylor, M. D.; Sircar, I.; Steffen, R. P. Agents for the treatment of congestive heart failure. Annu. Rep. Med. Chem. 1987, 22, 85-94.
2. Nomoto, Y.; Takai, H.; Ohno, T.; Kubo, K. Studies on cardiotonic agents. VI. Synthesis of novel 4,5-dihydro-3(2H)-pyridazinone derivatives carrying some benzoheterocycles at the 6-position. Chem. Pharm. Bull. 1991, 39, 352-357.
3. 2+ sensitizing effect. Chem. Pharm. Bull. 1991, 39, 900-910.
4. Austel, V.; Heider, J.; Eberlein, W.; Diederen, W.; Haarman, W. U.S. Patent 4 361 563; Chem. Abstr. 1983, 98, 72123p.
5. Narimatsu, A.; Kitada, Y.; Satoh, N.; Suzuki, R.; Okushima, H. Cardiovascular pharmacology of 6-[4-(4′-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride, a novel and potent cardiotonic agent with vasodilator properties. Arzneim.-Forsch. 1987, 37, 398-406.
6. Kitada, Y.; Narimatsu, A.; Suzuki, R.; Endoh, M.; Taira, N. Does the positive inotropic action of a novel cardiotonic agent, MCI-154, involve mechanisms other than cyclic AMP? J. Pharmacol. Exp. Ther. 1987, 243, 639-645.
7. Fujino, K.; Sperelakis, N.; Solaro, R. J. Differential effects of d-and l-pimobendan on cardiac myofilament calcium sensitivity. J. Pharmacol. Exp. Ther. 1988, 247, 519-523.
8. Muller-Beckmann, B.; Freund, P.; Honerjäger, P.; Kling, L.; Ruegg, J. C. In vitro investigation on a new positive inotropic and vasodilating agent (BM 14.478) that increases myocardial cyclic AMP content and myofibrillar calcium sensitivity. J. Cardiovasc. Pharm. 1988, 11, 8-16.
9. Mcmahon, E. G.; Palomo, M. A.; Mehta, P.; Olins, G. M. Depressor and natriuretic effects of M&B22948, a guanosine cyclic 3′,5′-monophosphate selective phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther. 1989, 251, 1000-1005.
10. Wilkins, M. R.; Settle, S. L.; Needleman, P. Augmentation of the natriuretic activity of exogenous and endogenous atriopeptin in rats by inhibition of guanosine 3′,5′-cyclic monophosphate degradation. J. Clin. Invest. 1990, 85, 1274-1279.
11. Ohno, T.; Nagashima, K.; Moriyama, T.; Ishikawa, T.; Kubo, K.; Yamada, K. Vasorelaxant properties of KF15232, a new phosphodiesterase inhibitor. Can. J. Physiol. Pharmacol. 1994, 72 (Suppl. 1), 153.
12. Hauel, N.; Heider, J.; Stein, H.; Austel, V.; Riffen, M.; Biederen, W.; Haarmann, W. Ger. Patent 3006671; Chem. Abstr. 1981, 95, 203981e.
13. Fu, S.-C. J.; Birnbaum, S. M.; Greenstein, J. P. Influence of optically active acyl groups on the enzyme hydrolysis of N-acylated-L-amino acids. J. Am. Chem. Soc. 1954, 76, 6054-6058.
14. Owings, F. F.; Fox, M.; Kowalski, C. J.; Baine, N. H. An enantioselective synthesis of SK&F 93505, a key intermediate for preparing cardiotonic agents. J. Org. Chem. 1991, 56, 1963-1966.
15. ++ sensitivity of the contractile system by MCI-154, a novel cardiotonic agent, in chemically skinned fibers from the guinea pig papillary muscles. J. Pharmacol. Exp. Ther. 1987, 243, 633-638.
16. Sellin, L. C.; Alajoutsijarvi, A.; Törquist, K.; Fraser, M.; Pippuri, A.; Ojala, I. Inhibition of cardiac phosphodiesterase III by the novel cardiotonic agent 6-[4-(4′-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride. Arzneim.-Forsh. 1988, 38 (II), 1787-1789.
17. Weishaar, R. E.; Kobylarz-Singer, D. C.; Kaplan, H. R. Subclass of cyclic AMP phosphodiesterase in cardiac muscle. J. Mol. Cell. Cardiol. 1987, 19, 1025-1036.
18. (a) Torphy, T. J.; Cieslinski, L. B. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol. Pharmacol. 1990, 37, 206-214.
19. (b) Kincarid, R. L.; Manganiello, V. C. Assay of cyclic nucleotide phosphodiesterase using radiolabeled and fluorescent substrates. Methods Enzymol. 1988, 159, 457-470.
20. (a) Alousi, A. A.; Canter, J. M.; Montenaro, M. J.; Fort, D. J.; Ferrari, R. A. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J. Cardiovasc. Pharm. 1983, 5, 792-803.
21. (b) Alousi, A. A.; Stankus, G. P.; Stuart, J. C.; Walton, L. H. Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J. Cardiovasc. Pharm. 1983, 5, 804-11.
22. Bristol, J. A.; Sircar, I.; Moos, W. H.; Evans, D. B.; Weishaar, R. E. Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: Novel positive inotropic agents for the treatment of congestive heart failure. J. Med. Chem. 1984, 27, 1099-1101.
23. Robertson, D. W.; Krushinski, J. H.; Beedle, E. E.; Wyss, V.; Don Pollock, G.; Wilson, H.; Kauffman, R. F.; Hayes, J. S. Dihydropyridazinone cardiotonics: The discovery and inotropic activity of 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2- one. J. Med. Chem. 1986, 29, 1832-1840.
24. McEvoy, F. J.; Allen, G. R., Jr. 6-(Substituted phenyl)-5-substituted-4,5-dihydro-3(2H)-pyridazinones. Antihypertensive agents. J. Med. Chem. 1974, 17, 281-286.
25. (a) Franciosa, J. A.; Goldsmith, S. R.; Chor, J. N. Contrasting immediate and long-term effects of isosorbide dinitrate on exercise capacity in congestive heart failure. Am. J. Med. 1980, 69, 559-566.
26. (b) Leier, C. V.; Huss, P.; Magorien, R. D.; Unverferth, D. V. Improved exercise capacity and differing arterial and venous tolerance during chronic isosorbide dinitrate for congestive heart failure. Circulation 1983, 67, 817-822.